HHS Lyme Disease Roundtable: What Was Announced and What It Means
Policy, access and evidence · Updated November 7, 2026
The December 15, 2025 HHS Lyme disease roundtable brought patients, clinicians and researchers into a federal discussion of diagnostics and care. The announcements matter. Their practical meaning becomes clearer when we distinguish research funding, coordinated-care eligibility and scientific conclusions.[1]
Key points
- HHS announced renewed LymeX diagnostic efforts.
- CMS clarified coordinated-care support for eligible patients with complex conditions.
- That guidance is not a blanket promise to cover every treatment.
- A policy announcement does not determine the cause of an individual’s symptoms.
Correction · November 7, 2026
The earlier article implied new billing codes and broader insurance guarantees than the linked material established. It also inferred that animal persistence findings explain patients’ ongoing symptoms. This revision replaces the unrelated CMS citation, states eligibility conditions and separates policy from causal evidence.
Explore this guide
The announcements · Coverage conditions · Terminology and cause · Morgellons context
What the HHS Lyme disease roundtable announced
| Development | What the official sources support |
|---|---|
| LymeX renewal | HHS announced renewal of its $10 million diagnostic initiative with the Steven & Alexandra Cohen Foundation.[1] |
| Coordinated care | HHS linked to CMS guidance supporting eligible beneficiaries with Lyme disease and related complex conditions through Chronic Care Management.[1][2] |
| Lyme-IACCI terminology | HHS uses Lyme infection-associated chronic conditions and illnesses to describe enduring illness associated with Lyme disease.[3] |
These developments concern a research program and access to services. They do not themselves validate a diagnostic assay or demonstrate the effectiveness of a particular drug regimen.
Coverage still has eligibility conditions
CMS describes Chronic Care Management for people with two or more chronic conditions expected to last at least 12 months or until death, with specified risks to health or function. Its guidance includes some complex infection-associated conditions, including Lyme disease.[2]
That is more precise than saying all people with Lyme now qualify, or that every requested treatment will be reimbursed. A coordinated-care benefit is not a universal treatment-coverage decision. Predictions about private insurers following suit should be identified as predictions, not patient entitlements.
Technical note: guidance is different from a new treatment code
The official HHS announcement points to support through Chronic Care Management. It does not establish the earlier article’s claim that new Lyme-specific CMS codes guarantee access to long-term treatment. This revision describes the cited guidance rather than inferring a new billing entitlement from it.
Terminology and biological cause remain separate
HHS’s current Lyme page describes programs directed at infection-associated chronic illness. CDC’s current persistent-symptom page states that the cause of prolonged symptoms after Lyme treatment remains unknown. Readers should see the scope and wording of both sources rather than treating one event as settling that question.[3][4]
A statement about persistence in an experimental system also needs a separate evidentiary bridge before it explains a particular patient’s illness or establishes a treatment benefit. Recognition of suffering does not depend on having settled that mechanism.
What this means for Morgellons coverage
The roundtable concerns Lyme-related care and research. It is not a study establishing the cause of Morgellons. Our research library and Morgellons–Lyme explainer address that distinction.
Read the announcement and the eligibility rule together
An announcement explains a policy direction. The program guidance defines the conditions. Neither should be asked to do the work of a clinical study.
Sources and scope
1. U.S. Department of Health and Human Services. Secretary Kennedy Convenes Lyme Disease Patients and Providers to Announce New Diagnostic Efforts. December 15, 2025. Official announcement, not a clinical trial. ↩
2. Centers for Medicare & Medicaid Services. Chronic Care Management for Complex Conditions. Current eligibility guidance checked November 7, 2026. ↩
3. U.S. Department of Health and Human Services. Invisible Illness: Lyme Disease. Current HHS program and terminology page checked November 7, 2026. ↩
4. Centers for Disease Control and Prevention. Chronic Symptoms and Lyme Disease. June 26, 2026. Agency account of persistent-symptom uncertainty, distinct from the HHS event announcement. ↩
Free online course
Make sense of the evidence.
Work through six short lessons on skin findings, specimen context and research, including the 2026 publications. Take the quizzes, save your progress and earn a verifiable certificate of completion.
Free to read. An account is needed for saved progress and assessments. Educational completion, not medical certification or accredited continuing education.
Written by Jeremy Murphree, patient advocate. This is an educational policy explainer, not an insurance-coverage determination or treatment recommendation. Program pages can change; the sources were checked November 7, 2026.
Image note: the featured meeting scene is an editorial illustration from a Gemini image file, not a documentary photograph of the HHS roundtable.
